Skip to main content
Premium Trial:

Request an Annual Quote

Marina to Sell off Non-RNAi Asset to Cypress Bioscience

Premium

Marina Biotech said this week that it has signed an agreement to sell its patents and technology related to carbetocin, a long-acting analog of the hormone oxytocin, to Cypress Bioscience for an initial fee of $750,000 and potential milestones of up to $27 million.

According to Marina, the drug may potentially be used as an autism treatment. Nastech Pharmaceutical, the predecessor company of Marina, had advanced the compound through two phase I dose-escalation studies.

"While we remain focused on building value around our RNAi drug discovery platforms, the sale of our carbetocin assets to Cypress is another example of our efforts to monetize the legacy assets of our predecessor company," Marina President and CEO Michael French said in a statement. "We hope to use the potential downstream financial opportunity to further fund our RNAi-based drug discovery and development efforts."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more